TruthArchive.ai - Related Video Feed

A study comparing autistic children to their neurotypical siblings and unrelated neurotypical children revealed that autistic children often lack bifidobacteria, a crucial microbe abundant in newborns. The speaker is publishing a paper based on this research. Identical twins with autism, who were nonverbal and aggressive, shared elevated levels of three identical microbes and had zero bifidobacteria. After treatment focused on eliminating harmful microbes and increasing beneficial ones, both twins became fully verbal and non-aggressive within seven months. The speaker believes that the microbiome offers insights into the condition of these children, as microbes travel from the gut to the brain via nerves. The speaker emphasizes the need to focus on nonverbal, severely affected autistic children and criticizes the lack of research and therapeutics, especially in light of the high number of cases in California.

The speaker conducted a study on the effects of vaccines on the microbiome. They found that the Bifidobacteria, an important microbe for immunity, decreased in patients after vaccination. This led them to believe that the vaccine may be creating a bacteriophage that kills off certain microbes. They also observed a lack of Bifidobacteria in newborns born to vaccinated mothers, which could potentially be linked to autism. The speaker emphasized the importance of studying the microbiome in various diseases and highlighted the need to investigate what is causing the loss of Bifidobacteria. They shared their personal experience of trying to increase their Bifidobacteria through kefir but finding that many products claiming to contain it did not. This led them to further research and experimentation.

Case: a kid progressed from nonverbal to speaking, then to calmer behavior as his microbiome aligned with his sister. They are publishing a paper on 20 autistic children versus 23 neurotypical siblings and six non-neurotypical kids with no family history of autism. They found autistic kids lacked a very important microbe—bifidobacteria, the microbe newborns are born with; aging is loss of bifidobacteria. In these 20 autistic children, bifidobacteria were low or absent, unlike their siblings; even within the same household, neurotypical vs autistic, those inside fared worse, indicating gut dysbiosis. In two cases of identical twins, nonverbal and aggressive, the same three microbes were elevated at baseline, and both had zero bifidobacteria. Seven months later, the twins are verbal and non-aggressive. "Follow the microbiome" to see the answer; microbes travel from gut to brain. It is a crime to ignore that. California crisis; funding should go to research and therapeutics.

remember, I was the girl that basically was doing clinical trials for pharma, and I was doing fecal transplant. The first thing that came to me during COVID was I bet you it's in the stools. COVID can persist in the stools. Some people were asymptomatic and had COVID in their stools, but yet never had symptoms. What was the difference between those people? The difference was their bifidobacteria. Forty three severe patients with COVID had zero Bifidobacteria. Bifidobacteria was really the beginning for me. It was like, I wonder if that's the microbe I need to focus to neutralize COVID, to suppress COVID. If I have a lot of good bifidobacteria, maybe I'll be fine during COVID. Anecdotal studies like of kimchi and sauerkraut because obviously you can talk to people that ate sauerkraut and still got COVID.

Speaker 0: What results kind are you seeing with this study, with the fecal transplants in autistic children? We published that case supervised by the FDA: it was giving one sibling to another and the kid started verbalizing and he's not aggressive. He came to my office banging his head, breaking his teeth, and now he's responding and he's responding to treatment. He's communicating better. He's listening. He's doing classes. He's developing. Obviously, this kid was old when we got him, it's much better, we get better results and I think Doctor James Adams will tell you we get better results the younger they are. So that's one kid. We are on to more precise manipulations, kind of, with two twins that we did. We won a research award at the American College of Gastro about two weeks ago. And basically what we showed was two identical twins that had the same exact microbes at baseline. We manipulated the microbiome and then those microbes disappeared. But what we showed, which has been my path and my mission, save the Biff, is those kids, two identical twins, nine months later, their Bifidobacteria increased with whatever we did. And now they're verbalizing, they're fully reading, fully verbal. This is a beginning. The judge that judged my presentation said this is a proof of concept, right? That when you actually attain an engraftment of Bifidobacteria, these kids are improving. This is obviously my hypothesis, has been my hypothesis. To get to that, to do that, unfortunately, we do not have a stool assay right now that is valid, verified and reproducible in the consumer product, right? So this is the problem because parents are going to say, well, I gave my kids these probiotics and my kid's not improving. So what is Doctor Hazen saying? Well, the problem is if you don't see the increase in the bifidobacteria, your kid's not going to improve. And unfortunately, the tests that are out there are not valid, verified, or reproducible or anything that I could say, oh yeah, use this consumer product. We are developing a consumer product in full transparency, but we are far from that because of the fact that there are trillions of microbes in the gut. And as a responsible physician, I feel that I cannot give a report to a patient that says you have eubacteria or you have Alistope sphingoldi, but I have no idea what Alistope Spine Goldie does, if it's a good bug or a bad bug, because here's what's gonna happen. You're gonna get this lab test from me, you're gonna go to like a thousand doctors and they're gonna say, I have no idea what this test means. Which was the problem, by the way, at the beginning when all these tests were starting. Remember, UBiome, the company that sold all these tests? All these patients would get all these testing and then they would go to the GI doctor and the GI doctors would say, what is this? What the hell?

The speaker describes microbiome work on COVID-19 and post-mRNA vaccination, noting profound microbiome effects. “I was the girl that basically was doing clinical trials for pharma, and I was doing fecal transplant.” During COVID, “I bet you it's in the stools.” They found “COVID in the stools in a hundred percent of patients that were positive nasal swab” and that “COVID can persist in the stools.” Some asymptomatic individuals had COVID in stools; “the difference was their bifidobacteria.” Early anecdotal signals about kimchi and sauerkraut are discussed: “What's different between that population? Why is one person eating sauerkraut and kimchi is fine and another person not?” They observed that “forty three severe patients with COVID had zero Bifidobacteria.” They say they will “focus on Bifidobacteria, not the others, because there are some people that have zero bifidobacteria and never got COVID... create a resilience.” Finally, “So bifidobacteria was really the beginning for me. It was like, I wonder if that's the microbe I need to focus to neutralize COVID, to suppress COVID. If I have a lot of good bifidobacteria, maybe I'll be fine during COVID.”

"When fecal transplant showed more than, you know, improving C." "And one of my patients with Alzheimer's started remembering his daughter's date of birth, I said, what did I do? I just changed the microbiome." "I used the wife's microbiome to the husband." "It wasn't about pushing stools for Alzheimer's, but what was causing Alzheimer's? What microbes was the culprit?" "What microbes could suppress that microbe That's the culprit." "Babies have a lot of bifidobacteria, this important microbe that helps us decompose sugar." "And we saw a lot of Bifidobacteria in newborns." "There is obviously a consensus in the medical field because there's a lot of gynecologists now that are using the secretions from the vagina of the mom and smearing it on the baby that is born with C section to just make them healthier in a way."

The speaker conducted a study on the effects of vaccines on the microbiome. They found that the bifidobacteria, an important microbe for immunity, decreased in patients after vaccination. This led them to suspect that the vaccine may be causing the loss of bifidobacteria. They also discovered that newborns born to vaccinated mothers had no bifidobacteria in their microbiome, which raised concerns about the spike protein in breast milk. The speaker connected this research to their work on autism, where a loss of bifidobacteria is common. They emphasized the importance of studying the microbiome in various diseases and published posters on the loss of bifidobacteria in Crohn's and Lyme patients. The speaker hopes for further research to prove their hypothesis.

"I did a case where I did fecal transplant on a patient with Alzheimer's, and he could remember his daughter's date of birth six months after the procedure. So when I changed his microbiome, his poop in his colon, and gave him his wife's microbiome, who was super with it, started remembering things. So, when we start looking, and we're actually publishing stuff at ACG, because the deadline's today actually to publish for ACG American So, College of we have six abstracts coming up, and so we're showing the data on Alzheimer's, autism, long haulers. So, can't say vaccine injured because then it's not gonna be, you know, it's too controversial. So we have to stay within the but here's the problem. It should not be controversial. In order to advance science, in order to advance medicine, we need to be, better. We need to be better at listening"

"everybody is different." "We all have a fingerprint of our microbiome." "families are different." "the mom with triplets had an overgrowth of a certain group of microbes and the triplets, two of the triplets didn't have that microbe, but the one with autism had twice the amount of microbes that the mom had." "Engraftment determines success of a fecal transplant." "The kid started speaking, verbalizing." "We discovered that those people that had severe COVID had zero Bifidobacteria." "autistic kids have loss of bifidobacteria." "two identical twins, same exact microbes disappeared after nine months, and the Bifidobacteria goes up." "these kids are verbalizing, they're reading, they're counting." "Restoring the microbiome, saving the Bif, improving the bifidobacteria, and the kids are verbalizing." "this is a new revelation." "And I think it's going to be one of the biggest discoveries of this century in my opinion."

The speaker conducted a study on the effects of vaccines on the microbiome. They found that the bifidobacteria, an important microbe for immunity, decreased in patients after vaccination. This led them to suspect that the vaccine may be causing the loss of bifidobacteria. They also observed that newborns born to vaccinated mothers had no bifidobacteria in their microbiome, which raised concerns about the spike protein in breast milk. The speaker connected this research to their work on autism, where a loss of bifidobacteria is common. They emphasized the importance of studying the microbiome in various diseases and published posters on the loss of bifidobacteria in Crohn's and Lyme patients. The speaker hopes for further research to prove their hypothesis.

Speaker 0 notes anecdotal data and studies suggesting improvement of Parkinson’s disease with fecal microbiota transplant, mentioning China studies and that Johns Hopkins will start a study on it. They say we’re at the beginning of all this and, in the future, people may look back and see how archaic some early practices were, such as operating on a kidney instead of changing the microbiome. They reference data showing a signature microbiome in anxiety, noting that during COVID people were very anxious, and that this could be related to the media, the disease itself, or treatments. Speaker 1 observes there is open-minded thinking around health, especially preventative medicine, and a strong focus on autism at the moment. They ask for recommendations on approaching autism through the biome or more broadly. Speaker 0 responds that they would love to work with this government and governments worldwide to address autism, which affects every country and its children. They propose that COVID eroded trust in agencies, government, and pharmaceutical companies, and position themselves as someone who could rebuild that trust by driving proper research, focusing on the microbiome, and understanding diseases thoroughly. They advocate for international collaboration among clinicians and researchers, recounting experiences with colleagues in Italy and Germany who were conducting clinical trials. They express a willingness to coordinate with international colleagues to apply successful approaches to patients in the United States. Speaker 0 emphasizes the importance of global collaboration among clinicians to understand and fix autism in children, arguing that with one in twelve and a half boys in California affected, the issue demands attention. They ask, when is the right time to act—if not now, when? They conclude that the only way to fix this is for humanity to come together for the sake of children and future generations.

The speaker urges comprehensive autism assessment—microbiome analysis, neurological testing, and severity questionnaires—and invites people to join Progena Biome and get on the supportthemicrobiomeresearchfoundation.org list as funding allows. They frame the foundation as a nonprofit passion project, not a billion-dollar business, with vitamins and Biome Boosters sold to support research. They describe helping two twins whose mother initially paid for care, later supported by a foundation grant. Research questions include effects of cumin, lactoferrin, and Manuka honey on the microbiome, among others. They note FDA approval to run their protocol after years of regulatory work and substantial costs. The speaker calls on doctors and moms to join, saying Rome was not built in one day, and that if nothing is done, one in one kid will be autistic, with robots not the answer.

Bifidobacteria is presented as a common denominator lacking in individuals with autism, Alzheimer's, cancer, anxiety, bipolar disorder, obesity, and diabetes. The speaker questioned why young people were less affected by COVID-19 compared to older, diabetic, or obese individuals, and also why some seemingly healthy individuals with autoimmune conditions were severely affected. The speaker had pre-pandemic microbiome data and observed a correlation between bifidobacteria levels and COVID-19 outcomes. High-risk individuals exposed to COVID-19 who never contracted the virus had high levels of bifidobacteria, while those who contracted the virus multiple times had zero bifidobacteria. This observation reinforced the importance of bifidobacteria, further emphasized by treatment outcomes.

Interviewer: But you you have had this case. I know that you're still working on publishing the research where you, you know, you did this with twins. And we know that, you know, the twin studies are very popular for a bunch of reasons because the genetics are identical. What happened? Researcher: So from COVID and from doing that N of one, which took time, and then from trying to get this familial FMT, I had these kids that were basically coming in with autism. And I have a lot of patients that come to me that have tried so many things. So this case was two twins with the mom flew in from Tennessee, and I basically innovated. And but I said to her, I said, me let look at the microbiome. What was amazing about this case, and it's going to be a breakthrough, I don't want to say too much because it's going to be published in October at the American College of Gastro, but essentially we saw the identical out of trillions of microbes, we saw elevation, relative abundance of microbes elevated the same three phylum in both identical kids. And as we refluralized the gut, not with fecal transplant, but with methods, we basically noticed that those microbes disappeared and the good bacteria came on at the same time as speech started. So this was a breakthrough case, and it's going to be a breakthrough for the FDA once they see that. And we're going to use that. So we're going to start doing familial fecal transplant with the FDA. But we're hoping that we can bring this other method after, while we're doing familial fecal transplant to get the data to understand because this could have been a fluke with these two kids kids. But we wanna try to reproduce these two kids to see if we can do this for other kids. Mhmm. And therefore, maybe run two protocols, one with familial FMT, fecal microbiota transplant or intestinal microbiota transplant, and then another one with this protocol to see can we do this more safer, better, less playing with poop? Because this doesn't play with poop. Interviewer: Well, the other aspect is also that, as we said at the beginning, everybody's different, And so I think this is actually kind of important. There isn't a of Researcher: one size fits Interviewer: all solution when it comes to this. Researcher: There isn't a microbiome. There's trillions of microbes. And I gave you the example with the fungus or it could be a fungal, you know, overgrowth. It could be a you know, even doctor Feingold, who was the beginning, who basically said, let's try vancomycin. Right? Researcher: He said, let's vancomycin for kids with autism, and he saw something with vancomycin. What he was seeing was a destruction of a microbiome and a suppression of microbes that secrete toxins, which decreased the aggressivity the aggressivity of the kid but did not restore the speech. It was but at least it gave a quality of life to the family to say, hey. Our kid is not banging his head on the wall. And so vancomycin got us to this level. Researcher: Right? But vancomycin is not a permanent solution. The solution is really to restore the gut to the way it was, and the challenge that we have is we do not know what it was before. So when you take a kid and he has a destroyed microbiome, you don't know what his fingerprint of his microbiome was before to reproduce him. Right? Researcher: And you're right. Everybody's different, so everybody may not need the same, but we need to be more precise.

Politics should not have anything to do with treating kids with autism, because autism affects Democrats, Republicans, independents, races, religions, sexes. One in twelve and a half boys in California have autism; we must pay attention and put hands on deck. This is a physician-initiated IND (investigational new drug) trial: as a physician, I'll look at each child and ask why it worked in this kid and why it didn't work in that kid, and what I can do for the child it didn’t help. This is frontline clinical trials where physicians try different approaches. I'm focusing on the microbiome and an answer with fecal transplant. But what about the kid without a microbiome abnormality, or with a neurological primary? What about the kid with inflammatory bowel disease with destroyed mucosa that needs fixing before implanting microbes? What about brain-gut connections and genetic problems? These are different ways to treat.

The speaker conducted a study on the effects of vaccines on the microbiome. They found that the Bifidobacteria, an important microbe, decreased in patients before and after vaccination. This led them to believe that the vaccine may be creating a bacteriophage or bifidophage that kills off certain microbes. They also noticed a lack of bifidobacteria in newborns born to vaccinated mothers, which could potentially be linked to conditions like autism. The speaker emphasized the importance of studying the microbiome in various diseases and highlighted the need to investigate what is causing the loss of bifidobacteria. They conducted their own research and discovered that many products claiming to contain bifidobacteria actually did not. Overall, the speaker emphasized the importance of research in understanding and addressing these issues.

Severely autistic, nonverbal twins were observed to have identical microbiome compositions. After correcting their microbiomes to increase good microbes and decrease bad microbes, the twins became verbal and fully reading. This outcome is considered significant because clinical improvement was correlated with a measurable improvement in the microbiome assay.

Speaker 1 notes that ivermectin has broken through to the public sphere beyond COVID and is now discussed for many diseases. Speaker 0 asks where ivermectin stands in the scientific and medical community today and what other use cases exist for the medicine. Speaker 1 responds that thousands of doctors follow their data; 18,000 GI doctors see their data when they publish or present at the American College of Gastroenterology. Word-of-mouth in the medical community is a major form of marketing, with one doctor speaking to another. Referencing the COVID era, Speaker 1 mentions corruption and retractions, then describes ivermectin as having created a healthcare revolution where doctors have lined up to work to see other benefits of ivermectin without needing to ask permission to treat patients. A whole branch of healthcare is moving away from the same institute that Speaker 1 helped create drugs to market with his sisters. He says a group of doctors who had sponsored or helped pharma are turning away from pharma and exploring other methods to treat patients. He states his job is to unite doctors to see the truth, while bringing pharma back to being righteous and stopping data manipulation and scientist censorship. Speaker 1 references his book, Let’s Talk SH.T, acknowledging he could be wrong and challenging others to prove him wrong and reproduce the data to retract the hypothesis or paper. He emphasizes that the scientific process should be followed, especially when everything was done by the book and as well as he could. He adds that the research was not funded by others; it was funded by his savings. He created the microbiome research foundation with the goal of raising money to study kids with autism and to push an IND to the FDA, which cost about $600,000 to obtain FDA approval. He clarifies that no external party paid for this work, and he continues to struggle to raise funds to treat poor autistic kids who cannot afford expensive stool testing, drugs, and vitamins; they need help and everyone should step in to assist these kids. Speaker 1 concludes that their focus is fixing autism, with the aim of later addressing Parkinson’s, Alzheimer’s, and cancer.

Dr. Feingold pioneered vancomycin and fecal transplants for autism, holding a patent with Dr. Barodi. The speaker began using fecal transplants to treat an autistic 17-year-old who was nonverbal and self-injurious, obtaining FDA approval for the case. The patient improved, speaking and ceasing self-harm. Feingold believed autism was caused by an overgrowth of *desulfa vibrio* or *Clostridium perfringens*. However, the speaker found *Lactobacillus animalis* and high proteobacteria levels, but no bifida bacteria in the patient, suggesting autism's microbial profile varies. Analyzing hundreds of stool samples from autistic children, the speaker aims to identify unnamed microbes linked to autism. Dr. Adams' fecal transplant capsules improved 50% of autistic children in a study, but 50% did not improve, suggesting multiple factors are at play. The speaker hypothesizes that donor compatibility is a factor in fecal transplant success for autism, though there is currently no data on this.

Bifidobacteria are important for immunity, but they are not the only important microbe. The speaker notes that bifidobacteria are the microbe that is disappearing. Analyzing thousands of stool samples, out of 4,000 stool samples, there are only four that can be said with certainty “these are both microbiomes.” Out of the thousand samples analyzed, less than five percent have bifidobacteria. The speaker highlights that loss of bifidobacteria is not universally linked to all conditions. It is present in Alzheimer's disease, with Alzheimer's patients having lots of bifidobacteria; Lyme disease patients also have lots of bifidobacteria. Crohn’s patients that have never been treated have lots of bifidobacteria. In autistic kids, there is enough data now; they showed data initially, and now more data and more labs reproducing that data show that there are lots of bifidobacteria in autism. The speaker mentions that “Loss of bifidobacteria in autism” can be addressed by replenishing bifidobacteria, and refers to this as proof of concept that the judge at the American College of Gastroenterology acknowledged, noting that this is what is needed to advance science to understand. Loss of bifidobacteria was also noticed in patients with invasive cancer. The speaker says they published that data at the American College of Gastroenterology and presented at Digestive Disease Week, showing that if a patient had a non-aggressive cancer, they had a better level of bifidobacteria than a patient with invasive cancer who has zero. Regarding therapeutic implications, the speaker asks whether modulating the gut to improve bifidobacteria is feasible and notes collaboration with multiple centers, including MD Anderson. The implication is to start modulating the gut and improving bifidobacteria in cancer patients rather than relying solely on chemotherapy and immunotherapy. In summary, the research conducted at Progena Biome—a research lab—focuses on bifidobacteria, its variable presence across diseases, its potential replenishment in autism, and its association with cancer progression, highlighting ongoing work to modulate the gut microbiome as a therapeutic strategy.

Using available information to create breakthroughs, the speaker cites Penelope's schoolmates—severely autistic, nonverbal and aggressive—and notes that some turned around when parents were intensely involved with detox, a personal trainer, a chef, antibiotics, the IVs, vitamins, and supplements. With the ability to analyze the microbiome of kids with autism, they argue this is not a universal treatment plan; some children improve with antifungals because of fungal overgrowth, while others do not. The key is looking at each child’s microbiome: a fungus; a toxin-secreting bacteria; or other factors. For example, fecal transplant might help children with Clostridium difficile. They stress that autism likely results from multiple microbes and factors, not a single causation, and that calculated, population-level research is needed. Cerumen is mentioned as an example of partial success, illustrating the complexity and the need for detective work; it’s not a one-pill solution.

The speaker discusses striking clinical observations linking the microbiome, specifically Bifidobacteria, to major improvements in two areas: autism and cancer. They reference two twins with autism who were nonverbal. After improving and manipulating their microbiome, the twins are described as completely fully verbal and reading books, highlighting the potential power of Bifidobacteria in their treatment approach. The speaker then shifts to oncology, noting they recently finished speaking at the Win Consortium in front of academic oncologists. They presented data on a patient with stage four head and neck cancer who “shrunk by increasing the bifidobacteria,” emphasizing that the observed tumor response was attributed to the microbiome rather than surgery, chemotherapy, or radiation. This observation is described as illustrating “the power of the bifidobacteria.” Following this, the speaker describes how these findings are opening new collaborations with major cancer centers, specifically naming Penn State and MD Anderson, as oncologists recognize that while immunotherapy is being given, there is interest in long-term outcomes and better survival. The implication is that there may be an element being missed related to the microbiome. Finally, the speaker mentions ongoing research on neuroblastoma, focusing on Bifidobacteria and the broader microbiome to determine how immunotherapy can help on one side and how boosting the microbiome can help on the other. The overarching message is that “we tend to forget about the microbiome and immunity starts in the gut,” suggesting a central role for the gut microbiome in modulating immune responses and therapeutic outcomes.

Two twins with severe autism and nonverbal communication are described; their microbiome is identically the same, with the same groups of microbes. After you correct their microbiome, you flip that formula to becoming good microbes high, low bad microbes down. And those kids are speaking and fully verbal, fully reading, that's the gold. Because now you know, well, have clinical significance, but I also have a microbiome assay that tells me that my kid has improved. The speaker emphasizes 'the gold' as the result of these changes and references a microbiome assay to demonstrate improvement. This is presented as significant.

The speaker conducted a study on the effects of vaccines on the microbiome. They found that the bifidobacteria, an important microbe for immunity, decreased in patients after vaccination. This led them to suspect that the vaccine may be causing the loss of bifidobacteria. They also observed a lack of bifidobacteria in newborns born to vaccinated mothers, which raised concerns about the spike protein in breast milk. The speaker connected this research to their work on autism, where a loss of bifidobacteria is common. They emphasized the importance of studying the microbiome in various diseases and published posters on the loss of bifidobacteria in Crohn's and Lyme patients. The speaker hopes for further research to prove their hypothesis.